trial · primary record
Osimertinib
Non Small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 80 |
| Primary completion | 2026-01-24 |
| Primary endpoint | Progression free survival |
| Registry ID | NCT04769388 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:54.111Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04769388
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Osimertinib · compound